The results are consistent with the findings that ADAM9 is highly expressed and high levels of ADAM9 expression predict a worse prognosis in other types of solid malignant tumors (9–15), suggesting that ADAM9 is a novel and valuable prognostic biomarker for NSCLC. Here, ADAM9 is linked to non-small cell lung carcinoma.